| Latest | F'cast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -20.2% | n/a |
| ROCE | 262.5% |
| Latest | F'cast | |
|---|---|---|
| P/E | n/a | n/a |
| PEG | n/a | n/a |
| Pr/Revenue | 1.6 | n/a |
| Pr/Book | n/a |
| Latest | F'cast | |
|---|---|---|
| Revenue | 54.4% | n/a |
| PBT | n/a | n/a |
| EPS | n/a | n/a |
| DPS | n/a | n/a |
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-21 | 1.52 | (19.91) | (10.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-22 | 5.50 | (49.43) | (21.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-23 | 13.09 | (32.38) | (5.00)p | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-24 | 32.18 | (26.56) | (3.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
| 31-Dec-25 | 49.70 | (17.14) | (2.00)¢ | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
| Total Voting Rights | 03-Aug-2026 | 12:02 | RNS |
| Q2 and H1 2026 Trading Update | 30-Jul-2026 | 07:00 | RNS |
| ACCRUFeR® Phase 3 pediatric trial published | 28-Jul-2026 | 07:00 | RNS |
| Shield Therapeutics reports positive Q1 earnings | 01-May-2026 | ShareCast |
| Shield's Accrufer MA application accepted in China | 03-Mar-2026 | ShareCast |
| Total Voting Rights | 02-Jan-2026 | ShareCast |
No deals were found in the last 28 days.
| Currency | UK Pounds |
| Share Price | 4.00p |
| Change Today | 0.30p |
| % Change | 8.11 % |
| 52 Week High | 12.20p |
| 52 Week Low | 3.70p |
| Volume | 3,530,794 |
| Shares Issued | 1,069.91m |
| Market Cap | £42.80m |
| Beta | 0.03 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:27 | 51,408 @ 3.90p |
| 16:26 | 127,974 @ 3.91p |
| 16:26 | 128,384 @ 3.90p |
| 16:24 | 130 @ 4.03p |
| 16:24 | 127,892 @ 3.92p |
You are here: research